3rd Epigenetic–Targeted Drug Discovery & Development Summit

Welcome to the 3rd Epigenetic–Targeted Drug Discovery & Development Summit

Taking place in person for the first time this summer, the 3rd Annual Epigenetic-Targeted Drug Discovery & Development Summit is the first and only devoted industry-specific forum exclusively focused on showcasing the latest research and pre-clinical and translational development of small-molecule, and other epigenetic modulators of gene expression, whilst providing pivotal insights to kickstart the next generation of clinically defining therapeutics and help overcome early-stage clinical trial challenges.

Attendees can expect to hear the latest discovery, preclinical and translational advancements in therapeutic interventions targeting all areas of epigenetic machinery including DNA methylation, histone post-translational modifications, chromatin remodeling, and non-coding RNAs (ncRNAs).

Tickets    https://go.evvnt.com/1102920-2?pid=2809 
Brochure https://go.evvnt.com/1102920-3?pid=2809 

Prices:
Industry Pricing - Conference Only USD 2999.00
Industry Pricing - Conference + 1 Workshop USD 3648.00
Industry Pricing - Conference + 2 Workshops USD 4297.00
Academic Pricing - Conference Only USD 2599.00
Academic Pricing - Conference + 1 Workshop USD 3148.00
Academic Pricing - Conference + 2 Workshops USD 3697.00
Standard Pricing - Conference Only USD 3599.00
Standard Pricing - Conference + 1 Workshop USD 4348.00
Standard Pricing - Conference + 2 Workshops USD 5097.00

Speakers: Alejandra Raimondi, Vice President Biological Sciences, Epizyme, Alon Goren, Assistant Professor, University of San Diego California (UCSD), Asad Taherbhoy, Director of Drug Discovery, Foghorn Therapeutics, Ayman El-Guindy, Chief Scientific Officer, Viracta Therapeutics, Claes Wahlestedt, Associate Dean & Center Director for Therapeutic Innovation; Chief Scientific Officer University of Miami Miller School of Medicine; Epigenetix, David Bumcrot, Chief Scientific Officer, CAMP4 Therapeutics, Henry Long, Scientific Director Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society, Laura Poling, Director of Biology, C4 Therapeutics, Matthew Oser, Assistant Professor of Medicine Dana Farber Cancer Institute, Harvard Medical School, Paloma Cejas, Assistant Director for Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Peter Atadja, Co-Founder & Chief Scientific Officer, K36 Therapeutics, Philipp Mews, Co-Founder, EpiVario, Rich Bennett, Assistant Professor, University of Florida, Shikhar Sharma, Research Fellow, Pfizer, Steven Fractman, President & Chief Executive Officer, Onconova Therapeutics, Thomas Paul. Senior Director. Pfizer

Read More

View Less